Human crp quantikine elisa

A subset of participants (N = 98) provided blood samples, which were used to measure circulating levels of CRP. Blood samples were collected by venipuncture into EDTA tubes, placed on ice, centrifuged for acquisition of plasma, and stored at -80 °C for batch testing. CRP levels were determined utilizing the high-sensitivity Human CRP Quantikine ELISA (R&D Systems) according to the manufacturer's protocol with a lower limit of detection of 0.2 mg/L, as previously described [52] . Samples were assayed in duplicate. The mean inter-assay CV was 5.7% and the mean instar-assay CV was 3.3%. For the small proportion (8%, n = 8) of samples with CRP levels below the limit of detection (0.2 mg/L), a value of 0.2 mg/L was assigned. Participants were asked to report if they experienced any sickness symptoms and/or received vaccinations within the two weeks preceding the blood draw.

Fifty-one participants provided blood samples at baseline (ibudilast: n=24; placebo: n=27). Blood samples were collected by venipuncture into EDTA tubes, placed on ice, centrifuged for acquisition of plasma, and stored at -80°C for batch testing. CRP levels were determined utilizing the high-sensitivity Human CRP Quantikine ELISA (R&D Systems) according to the manufacturer's protocol with a lower limit of detection of 0.2 mg/L. Samples were assayed in duplicate. Intra-and inter-assay variation of the tests was <6.1%. For the small proportion (4%, n=2) of samples with CRP concentrations above the upper limited of the standard curve (>25 mg/L) a value of 25 mg/L was assigned. For the small proportion (10%, n=5) of samples with CRP levels below the limit of detection (0.2 mg/L), a value of 0.2 mg/L was assigned.